# Valneva (VALN) — News

VALN · NASDAQ · Stock

Canonical page: https://www.lighthorse.io/tickers/valn/news

## Recent headlines

- [French Pharma shares Genfit, Nanobiotix, Valneva down between 4.8% and 6.2%](https://www.ainvest.com/news/french-pharma-shares-genfit-nanobiotix-valneva-4-8-6-2-2610) — AInvest Wire, Oct 8, 2026
  On Monday, several French pharmaceutical stocks experienced declines, with Genfit S.A. (GNFT.PA), Nanobiotix, and Valneva all posting losses in the range of 4.8% to 6.2%. The drop comes amid broader market volatility and sector-specific pressures affecting biotech and pharmaceutical firms.…
- [Valneva SE shares down 3.9% after update on iXchIQ in the UK](https://www.ainvest.com/news/valneva-se-shares-3-9-update-ixchiq-uk-2610) — AInvest Wire, Oct 8, 2026
- [Valneva: Decision based on safety data review](https://www.ainvest.com/news/valneva-decision-based-safety-data-review-2610) — AInvest Wire, Oct 7, 2026
  Valneva SE (Nasdaq: VALN; Euronext Paris: VLA) has taken a series of actions regarding its chikungunya vaccine, IXCHIQ®, based on a comprehensive review of safety data. In January 2026, the company voluntarily withdrew its U.S. Biologics License Application (BLA) and Investigational New Drug (IND)…
- [Valneva SE - MHRA decision not associated with newly identified safety signal](https://www.ainvest.com/news/valneva-se-mhra-decision-newly-identified-safety-signal-2610) — AInvest Wire, Oct 7, 2026
  On February 13, 2026, Valneva SE (Nasdaq: VALN; Euronext Paris: VLA) announced that the United Kingdom’s Commission on Human Medicines (CHM) has updated its recommendations for the use of Valneva’s single-dose chikungunya vaccine, IXCHIQ®. The updated Prescribing Information (PI) includes…
- [Valneva SE - MHRA revokes UK marketing authorization for ixchIQ](https://www.ainvest.com/news/valneva-se-mhra-revokes-uk-marketing-authorization-ixchiq-2610) — AInvest Wire, Oct 7, 2026
  Valneva SE (Nasdaq: VALN; Euronext Paris: VLA) has recently experienced a regulatory setback in the United Kingdom, where the Medicines and Healthcare products Regulatory Agency (MHRA) has revoked the marketing authorization for its chikungunya vaccine, IXCHIQ®. This decision marks a significant…

---

Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.

This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.

Data provided by [AInvest](https://www.ainvest.com).